User menu

Strategies for data analyses in a high resolution H-1 NMR based metabolomics study of a mouse model of Batten disease

Bibliographic reference Pears, Michael R. ; Rubtsov, Denis ; Mitchison, Hannah M. ; Cooper, Jonathan D. ; Pearce, David A. ; et. al. Strategies for data analyses in a high resolution H-1 NMR based metabolomics study of a mouse model of Batten disease. In: Metabolomics, Vol. 3, no. 2, p. 121-136 (2007)
Permanent URL
  1. Behrens, P.F., Franz, P., Woodman, B., Lindenberg, K.S. and Landwehrmeyer, G.B. (2002). Impaired glutamate transport and glutamate–glutamine cycling: downstream effects of the Huntington mutation. Brain 125, 1908–1922.
  2. Bollard M.E., Murray A.J., Clarke K., Nicholson J.K., Griffin J.L. (2003) A study of metabolic compartmentation in the rat heart and cardiac mitochondria using high-resolution magic angle spinning 1H NMR spectroscopy. FEBS Lett. 553:73–78
  3. Brooks A.I., Chattopadhyay S., Mitchison H.M., Nussbaum R.L., Pearce D.A. (2003) Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease. Mol. Genet. Metab. 78:17–30
  4. Burbaeva, G., Boksha, I.S., Turishcheva, M.S., Vorobyeva, E.A., Savushkina, O.K. and Tereshkina, E.B. (2003). Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 675–680.
  5. Chattopadhyay S., Ito M., Cooper J.D., Brooks A.I., Curran T.M., Powers J.M., Pearce D.A. (2002) An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11:1421–1431
  6. Cooper J.D. (2003) Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr. Opin. Neurol. 16:121–128
  7. Eriksson L., Johansson E., Kettaneh-Wold N., Wold S. (1999) Introduction to Multi- and Megavariate Data Analysis Using Projection Methods (PCA and PLS). Umetrics, Umea, Sweden
  8. Gardiner R.M. (2002) Clinical features and molecular genetic basis of the neuronal ceroid lipofuscinoses. Adv. Neurol. 89:211–215
  9. Griffin J.L., Blenkiron C., Valonen P.K., Caldas C., Kauppinen R.A. (2006) High-resolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma. Anal. Chem. 78:1546–1552
  10. Griffin J.L., Cemal C.K., Pook M.A. (2004) Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol. Genomics 16:334–340
  11. Griffin, J.L., Muller, D., Woograsingh, R., Jowatt, V., Hindmarsh, A., Nicholson, J.K. and Martin, J.E. (2002). Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics. Physiol. Genomics 11, 195–203.
  12. Griffin J.L., Shockcor J.P. (2004) Metabolic profiles of cancer cells. Nat. Rev. Cancer 4:551–561
  13. Holmes E., Antti H. (2002) Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 127:1549–57
  14. Mitchison H.M., Bernard D.J., Greene N.D., Cooper J.D., Junaid M.A., Pullarkat R.K., de Vos N., Breuning M.H., Owens J.W., Mobley W.C., Gardiner R.M., Lake B.D., Taschner P.E., Nussbaum R.L. (1999) Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis. 6:321–334
  15. Mitchison H.M., Mole S.E. (2001) Neurodegenerative disease: the neuronal ceroid lipofuscinoses (Batten disease). Curr. Opin. Neurol. 14:795–803
  16. Ohdoi C., Nyhan W.L., Kuhara T. (2003) Chemical diagnosis of Lesch–Nyhan syndrome using gas chromatography-mass spectrometry detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 792:123–130
  17. Pears M.R., Cooper J.D., Mitchison H.M., Mortishire-Smith R.J., Pearce D.A., Griffin J.L. (2005) High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J. Biol. Chem. 280:42508–42514
  18. Petroff, O.A., Errante, L.D., Rothman, D.L., Kim, J.H. and Spencer, D.D. (2002). Glutamate-glutamine cycling in the epileptic human hippocampus. Epilepsia 43, 703–710.
  19. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9:684–697, 643
  20. Rozen S., Cudkowicz M.E., Bogdanov M., Matson W.R., Kristal B.S., Beecher C., Harrison S., Vouros V., Flarakos J., Vigneau-Callahan K., Matson T.D., Newhall K.M., Beal M.F., Brown R.H., Kaddurah-Daouk R. (2005) Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1:101–108
  21. Tsang T.M., Woodman B., McLoughlin G.A., Griffin J.L., Tabrizi S.J., Bates G.P., Holmes E. (2006) Metabolic characterization of the R6/2 transgenic mouse model of Huntington’s disease by high-resolution MAS 1H NMR spectroscopy. J. Proteome Res. 5:483–492
  22. Warne M.A., Lenz E.M., Osborn D., Weeks J.M., Nicholson J.K. (2000) An NMR-based metabonomic investigation of the toxic effects of 3-trifluoromethyl-aniline on the earthworm Eisenia veneta. Biomarkers 5:56–72
  23. Wisniewski K. E., Zhong N., Philippart M., Pheno/genotypic correlations of neuronal ceroid lipofuscinoses, 10.1212/wnl.57.4.576